News & Updates
Filter by Specialty:
FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.
FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
28 Sep 2022
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
27 Sep 2022
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
Some men who undergo artificial urinary sphincter (AUS) and inflatable penile prosthesis (IPP) surgery encounter a venous thromboembolism (VTE) event within 90 days of their operation, reports a study.
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
27 Sep 2022
Are healthcare workers more stressed out during the COVID-19 pandemic?
Burnout continues to be a burden among healthcare workers (HCWs) during the COVID-19 pandemic despite the lack of quality research with pre-COVID-19 data, according to a Singapore study.
Are healthcare workers more stressed out during the COVID-19 pandemic?
27 Sep 2022
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
Treatment with radiotherapy appears to result in more all-cause or prostate cancer-specific mortality (PCSM) compared with radical prostatectomy (RP), suggests a study.
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
27 Sep 2022
Add-on reslizumab cuts exacerbations, OCS use in severe eosinophilic asthma
Reslizumab, a biologic targeting interleukin(IL)-5, reduced severe asthma exacerbation rate and oral corticosteroid (OCS) use in individuals with severe eosinophilic asthma, according to a real-world study using patient-level data from RAPSODI*.
